home / stock / viri / viri news

VIRI News and Press, Virios Therapeutics Inc. From 04/16/21

Stock Information
Company Name: Virios Therapeutics Inc.
Stock Symbol: VIRI
Market: NASDAQ
Website: virios.com
Menu
VIRI VIRI Quote VIRI Short VIRI News VIRI Articles VIRI Message Board
Get VIRI Alerts

News, Short Squeeze, Breakout and More Instantly...
VIRI - Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, w...
VIRI - Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer,...

VIRI - Virios Therapeutics reports Q4 results

Virios Therapeutics (VIRI): Q4 GAAP EPS of -$1.25.Cash totaled $29.8MPress Release For further details see: Virios Therapeutics reports Q4 results

VIRI - Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended ...
VIRI - Virios Therapeutics: Highly Differentiated Mechanism Of Action In Fibromyalgia

The company believes that an abnormal immune response to Herpes Simplex Virus 1 (HSV-1) infection is responsible for chronic conditions like FM and IBS, representing a novel mechanism of action. There is currently no significantly effective treatment for 3.6M diagnosed FM patients. ...

VIRI - Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its fourth quarter and full year 2020 financial re...

VIRI - Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer,...
VIRI - Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Virios Therapeutics (VIRI) rises 10% premarket in reaction to the announcement it is collaborating with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome ((IBS)).The first step in the partnership is focused on designing...

VIRI - Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo C...

VIRI - Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that Greg Duncan, Chairman and Chief Executive Officer, and R. Michael Gendr...
Previous 10 Next 10